Trial Profile

Belatacept Conversion Trial in Renal Transplantation Revised Protocol 05 incorporating Protocol Amendment 08 + Pharmacogenetics Blood Sample Amendment 01 (version 4.0 dated 08-Aug-06)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belatacept (Primary) ; Ciclosporin; Tacrolimus
Indications Renal transplant rejection
Focus Adverse reactions; Biomarker; Therapeutic Use
Sponsors Bristol-Myers Squibb

Most Recent Events

11 Sep 2013 Results at 3 years presented at the 16th Congress of the European Society for Organ Transplantation.
01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
13 Jun 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com